A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

ClinicalTrials.gov ID: NCT04104776

Public ClinicalTrials.gov record NCT04104776. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 15, 2026, 6:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Study identification

NCT ID: NCT04104776
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 275 participants

Conditions and interventions

Conditions

Interventions

Enzalutamide Drug
Tulmimetostat Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 17, 2019
Primary completion: Feb 26, 2030
Completion: Feb 26, 2030
Last update posted: May 14, 2025

2019 – 2030

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Winship Cancer Institute of Emory University	Atlanta	Georgia	30322-1013	Recruiting
University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
University of Maryland - Marlene and Stewart Greenebaum Cancer Center	Baltimore	Maryland	21201	Withdrawn
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215-5450	Recruiting
University of Michigan Hospital	Ann Arbor	Michigan	48109	Withdrawn
South Texas Accelerated Research Therapeutics (Start) - Midwest Location	Grand Rapids	Michigan	49546	Recruiting
Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center	New York	New York	10016	Recruiting
Weill Medical College of Cornell University	New York	New York	10065	Withdrawn
Montefiore Einstein Center for Cancer Care	The Bronx	New York	10467-2490	Withdrawn
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	Withdrawn
Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
South Texas Accelerated Research Therapeutics	San Antonio	Texas	78229	Recruiting
University of Virginia Health System	Charlottesville	Virginia	22908	Recruiting
Swedish Cancer Institute	Seattle	Washington	98104	Recruiting
Fred Hutchinson Cancer	Seattle	Washington	98109-1023	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04104776, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 14, 2025 · Synced May 15, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04104776 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →